In vitro studies have shown that drug concentrations equivalent to five times the in vivo dose had no effect on the proliferative rate or viability of the MTLn3 cells. Moreover, the proliferative rate of these cells in culture was significantly increased when exposed to soluble mast cell products. Thus our data indicate that a mast cell-stabilising compound has significant benefits in reducing tumour growth in vivo, an observation which supports the concept that mast cell: tumour cell interactions are important for the growth and invasive properties demonstrated by this model of breast carcinoma.
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Invasion and metastasis are cardinal features of malignant tumours and the complexity of these phenomena is well recognised (Fidler & Hart, 1982; Liotta, 1984; Nicolson, 1988) . Tumour cell interactions with the interstitial stroma or specific host cells may be of prime importance in determining invasive and metastatic behaviour (Yamada et al., 1985; Woolley, 1984; Dabbous et al., 1986a) . Stromal changes including extensive collagen degradation have been observed, and there is substantial evidence for the release of collagenolytic enzymes by invasive tumour cells (Dabbous et al., 1983; 1986a and b; Liotta et al., 1982; Woolley 1982) . The importance of host-tumour cell-cell interactions and the potential participation of both tumour cells and adjacent host cells in matrix degradation has been demonstrated by numerous in vitro studies (Bauer et al., 1979; Biswas, 1982; Dabbous et al., 1983; 1986a and b) .
The presence of mast cells at the tumour-host junction of several types of tumour has been recognised (Hartveit, 1981; Hartveit et al., 1984; Parwaresch et al., 1985; Dabbous et al., 1986a) . Although it has been suggested that mast cells are important in connective tissue diseases (Smyth & Gum, 1958; Lewis & Austen, 1981) their functional role in tumour behaviour has remained speculative and controverisal (Selye, 1965; Broom & Alexander, 1975a; Ionov, 1989) . Our recent observations of stromal lysis associated with mast cell degranulation at the tumour periphery of rat mammary adenocarcinoma suggested that mast cells could contribute directly to matrix degradation, either by the release of their own proteinases or by modulation of the collagenolytic activity of surrounding cells (Dabbous et al., 1986a (Dabbous et al., , 1986b . To determine the physiological role of mast cells in this context we have treated experimental rats with the effective mast cell-stabilising compound FPL 55618 and have examined its effect on the development of the rat mammary adenocarcinoma. We report here that the pharmacological elimination of mast cell activity in vivo resulted in significant inhibition of tumour growth, an observation supported by in vitro studies which showed that soluble mast cell products enhanced the proliferative rate of these tumour cells.
Materials and methods

Drug preparation
The Fisons compound FPL 55618 [8-allyl-5-(3-methylbutyloxy) -4 -oxo -8-prop-2-enyl4H-I-benzopyran-2-carboxylic acid] Na salt is a monochrome which is structurally related to disodium cromoglycate. It is a mast cell stabiliser 87-times more potent than the latter in the rat passive cutaneous anaphylaxis test following intravenous administration. The compound was progressed to man but was found, following topical administration, to have only minimal activity against human antigen challenge (Cairns, 1980; Suschitzky & Sheard, 1984 (Bromley & Woolley, 1984) or acidified Toluidine blue. Sections were also counter stained with 0.25% Azure 11-0.25% methylene Blue in 0.25% Borax.
Tumour cell proliferation
Tumour cells were plated out at 5.104 cellsml-' in 6-well cluster dishes in DMEM-10% FCS for 24h. The medium was changed to DMEM with and without FPL 55618 at concentrations of 1 and 5 fig ml-' and the cells were incubated for 3 days at 37'C in a water-saturated atmosphere of 5% CO2 in air. Cells were detached by trypsinisation and counted using a Coulter Counter.
Soluble mast cell products (MCP) were prepared from purified rat peritoneal mast cells and Furth mouse mastocytoma cells as described previously (Dabbous et al., 1986a) . MCP in DMEM was adjusted to the equivalent of 106 mast cellsml-' and used in the cell proliferation assay described above. Similar concentrations of cells from the nonmetastatic MTLn2 rat tumour cell line and the human breast carcinoma cell-line (8701 -BC) were extracted in an identical manner as the mast cells to provide control and comparative data. (Table II) . This 'rebound' effect was an impressive response to withdrawal of the mast cell stabiliser, and was a consistent observation in three separate experiments.
Results
Rats injected with
Careful examination at autopsy on day 24 showed that three animals in the control group had developed metastatic lesions in the axillary lymph node and abdominal region, while no visible metastasis was detected in the test group during the drug administration. Seven days after termination of the drug treatment metastatic deposits were observed in the axillary lymph node in one animal from each group. Although histologic examination showed no evidence of lung colonisation by spontaneous metastasis after 24 days of tumour growth, all animals showed lungs with edematous widening of alveolar septa (data not shown). In this tumour system, additional time is usually required for gross lung metastasis to be evident (Neri et al., 1982 (Figure 3) .
The ability of mast cells to stimulate the proliferative rate of MTLn3 cells in vitro is shown in Figure 4 . Tumour cells incubated with soluble mast cell products of either rat or mouse origin showed an increased rate of proliferation. By contrast the addition of similarly prepared extracts derived from rat and human tumour cells produced no increase in the proliferative rate. Moreover, the MCP-stimulation of proliferation was found to be concentration dependent (Figure 4) (Lewis & Austen, 1981; Parwaresch et al., 1985; Roche, 1986; Serafin & Austen, 1987) , and the association of mast cells with a variety of tumours has long been recognised (Ehrlich, 1879; Hartveit, 1981; Hartveit et al., 1984; Roche, 1985 Roche, , 1986 Dabbous et al., 1986a (Csaba et al., 1961; Graham & Graham, 1966; Parwaresch et al., 1985) , but recent studies have supported a more direct interaction with tumour cells, especially interactions which facilitate tumour growth (Nordlund & Askenase, 1983; Roche, 1985; Norrby, 1985) . Previous studies have used mast cell-stabilising compounds to examine the relative contribution of these cells to tumour development (Nordlund & Askenase, 1983; Roche, 1986) (Dabbous et al., 1986a) yet these were commonly seen in the drug-treated tumour specimens. The rapid tumour growth that followed withdrawal of the drug was shown histologically to be associated with an increase in mast cell activation and degranulation. One striking observation was the granule depletion of intratumoural mast cells within 2-3 days of withholding FPL 55618 treatment, subse- quently giving rise to negligible mast cells within the tumour and signs of degranulation by those surrounding the growing tumour. Such observations suggest that the accelerated growth of the tumour reflects a 'rebound' effect whereby mast cells, freed from their pharmacological restraint, contribute a local and concentrated supply of growth factors/ mediators. The association of mast cell activation with localised matrix dissolution has been noted (Norrby & Enestrom, 1984 , Dabbous et al., 1986a and was much in evidence in the present study. Mast cells contain the potent serine proteinases tryptase and chymase (Schwartz, 1989) which are functional at neutral pH. Although much is known about the physicochemical properties of these enzymes, relatively little is known about their natural protein substrates. However tryptase is reported to activate pro-stromelysin (MMP-3) with its subsequent activation of procollagenase (Gruber et al., 1989) and resultant collagenolysis. Moreover, mast cell products were shown to stimulate the production of collagenase from both fibroblasts and rat tumour cells in vitro and also to activate the collagenase precursor (Yoffe et al., 1984; Dabbous et al., 1986a) .
The stimuli that induce mast cell degranulation have been the subject of many reviews which usually focus on IgEmediated-immune reactions. IgE-antibodies specific to tumour antigens have been reported for specific animal tumours (Sweeney & Seibel, 1973; Bartholomaeus et al., 1974; Bartholomaeus & Keast, 1972; Broom & Alexander, 1975b) , but as yet it is uncertain whether such antibodies are formed in the rat 13762NF mammary adenocarcinoma. In addition to IgE-mediated Roche, 1985; Baeza et al., 1989 (Roche, 1985 (Roche, , 1986 . Mast cell heparin has also been implicated in tumourassociated angiogenesis where it stimulates endothelial cell proliferation and migration (Azizkhan et al., 1980) , and recent in vivo studies with mast cell-deficient mice have demonstrated a role for mast cells in tumour angiogenesis (Starkey et al., 1988) . Since continued tumour growth is dependent upon the ingrowth and supply of new vasculature (Kessler et al., 1976) it is possible that the inhibition of tumour growth reported here with FPL 55618 is explained not only by the prevention of a direct stimulation of tumour cell proliferation, but also by a reduction in the extent of neovascularisation. At present the relative contribution of these two aspects to tumour growth are unknown, as indeed are other indirect mechanisms involving lymphocytes, macrophages and fibroblasts -all cells which may be 'activated' by mast cell mediators. Histamine is also a potential stimulus for tumour growth (Bartholeyns & Bouclier, 1984; Norrby, 1985) , but (Dabbous et al., 1986a,b) . Such activities, together with the production of growth factors and localised oedema would promote the disruption of homeostasis and could well favour tumour growth and invasion. The reduction in tumour growth effected by the mast cell-stabilising compound FPL 55618 supports the hypothesis that local mast cell activation at the tumour peripherpy contributes significantly to tumour growth and development. 
